Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06313814
Other study ID # DE RKEB/IKEB 5622-2020
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date June 1, 2023
Est. completion date December 2025

Study information

Verified date April 2024
Source University of Debrecen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to assess ginger's effect on patients with functional dyspepsia. The main question[s] it aims to answer are: 1. Does ginger intake improve functional dyspepsia symptoms? 2. Does ginger intake decrease the body fat content among patients with functional dyspepsia? Dyspepsia patients will be asked to take 540 mg of ginger capsule twice a day. Researchers will assess if there is an improvement in the symptoms of the disease and the fat content. [ to see if gingers effect.


Description:

Brief description of the study: Currently, the options for managing functional dyspepsia are limited and far from ideal. Few conducted studies showed that ginger consumption has a therapeutic and preventive effect on functional dyspepsia however, the results were not conclusive. Therefore, this study will try to investigate the effect of ginger supplementation on functional dyspepsia symptoms and body fat content among patients with Functional dyspepsia. Volunteers with functional dyspepsia 62 participants will be will take as tablets containing 540mg ginger capsule twice a day for four weeks with follow-up. Functional dyspepsia symptoms will be asked before and after the intervention using a questionnaire based on the symptoms of Rome IV criteria, including gastric fullness, early satiety, nausea, vomiting, belching, epigastric pain and heartburn which will be graded through visual analog scales (0- 10 scores) and measured for the body contents. Method and Materials Sample size, sample selection: The study will include 62 volunteers with functional dyspepsia, female and male participants between the ages of 18 and 72 years. Study design This study is a before-after interventional study of patients with functional dyspepsia who come to internal medicine, at the University of Debrecen. Initiator of the investigation: Mrs. Lemlem Gebremariam Aregawi, PhD student in Nutritional sciences Dr. Zoltán Csiki, Supervisor Executor of the study: 1. Mrs. Lemlem Gebremariam Aregawi, PhD student in Nutritional sciences Doctoral school of pharmacology and pharmacotherapy, University of Debrecen Tel- +36204027611 E-mail: lemgmed@yahoo.com 2. Dr. Zoltán Csiki, Supervisor Gastroenterologist DE Medical and Health Sciences Center Department: Institute of Internal Medicine - III. s. Department of Internal Medicine Email: csikiz@gmail.com Test site: University of Debrecen OEC, Institute of Internal Medicine - III. s. Clinic of Internal Medicine Form and process of the examination: The examination is performed by a specialist (gastroenterologist) and nutrition student of the Institute of Internal Medicine with the help of section assistants familiar with the in-body measurement to measure body minerals, fat, muscle, water and BMI. In the case of each person examined, a form is filled in, which is also recorded in electronic form. The results of the physical examination of this participant as well as the measured results will be recorded. Body composition analyzer (InBody720): Patient requirements to be included: empty stomach, empty bladder, light clothes and no shoes for measurement in the early morning on the body composition analyzer. Patients with a pacemaker or with metal in the body will be excluded from measurement on this instrument. Dosage: Volunteers will take 540mg of ginger capsule twice a day for four weeks. Dosage Attached: In a separate dossier for each surveyed consumer, a statement of consent. Design of the study: before and after the interventional study Study subject: volunteer consumers, men, women (18 - 72 years). Meals: Diet intervention- 100% ginger powder ground 540mg capsule twice a day dose will be used: each component is characterized by elevated stability. It is prepared using extraction procedures suitable for ingredients of the health food market. The capsule will be provided free of charge and specifically designed for this study. All patients will be instructed to take one capsule immediately before starting lunch and dinner. During 30 days before the beginning of the study and the 28 days of intervention treatment, all patients will be asked to avoid the use of prokinetic and antisecretory (H2 receptor inhibitors and proton pump inhibitors) drugs. All patients will be also asked to limit the consumption of alcoholic beverages (less than or equal to two drinks per day). Study group Study group: 62 FD patients Response variables (Dependent variables) - functional dyspepsia symptoms - body contents, muscle, fat, minerals and water Task details: - Preparation, recruitment of consumers, and selection of participants. - Signing of prospectuses and statements of consent. - Carry out a preliminary examination among the applicants. Before - Self-completion questionnaire. - Performing in-body tests - Evaluation of results. Data analysis method: Data will be analyzed using SPSS software, version 23.0 (IBM Corp., Armonk, NY, USA). Results will be reported as mean (SD) and median (IQR). The Wilcoxon signed rank test will be used to assess the differences in GI symptoms before and after ginger supplementation. The difference between the concentrations at the given time points (initial concentration) will be calculated, the statistical procedure being the repeat t-test. If the background variables become inhomogeneous, it may be necessary to include covariates in the statistical analysis, in which case covariance analysis will be used. If the normality of the data is not adequate for the test or a normal data distribution cannot be transformed, the non-parametric test will be used. We will examine whether the measured parameters change significantly. The significance level will be set at P = 0.05.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 62
Est. completion date December 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 72 Years
Eligibility Inclusion Criteria: - Patients suffering from Functional dyspepsia symptoms Exclusion Criteria: - Patients with relevant gastroesophageal reflux symptoms (retrosternal pain, burning, or regurgitation) as well as patients with clear evidence of irritable bowel syndrome will not be included. Patients under treatment with pharmacological substances that could influence the gastrointestinal system, such as prokinetics, ursodeoxycholic acid (UDCA), nonsteroidal anti-inflammatory drugs (NSAIDs), cholagogues, protonpump inhibitors, and H2 blockers, will be asked to interrupt this treatment for one month before starting the study treatment. Moreover, patients with a previous diagnosis of cancer or with previous surgery of the upper gastrointestinal tract or of the biliopancreatic system (except for cholecystectomy) and patients with active HP infection or with gastric or duodenal ulcer, as well as pregnant women, will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Swanson ginger capsule
Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties. Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond.

Locations

Country Name City State
Hungary University of Debrecen Debrecen

Sponsors (1)

Lead Sponsor Collaborator
University of Debrecen

Country where clinical trial is conducted

Hungary, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional Dyspepsia Symptom Severity This study will evaluate and measure the expected improvements in functional dyspepsia symptoms. It will be assessed by the Nepean Dyspepsia Index (NDI) questionnaire, among 62 patients with functional dyspepsia treated with ginger supplementation compared to the baseline, by the end of the four-week intervention. This measure focuses on the reduction in symptoms such as pain, discomfort, bloating, and early satiety. Each item on the Nepean Dyspepsia Index questionnaire is usually scored on a Likert scale, with higher scores representing more severe symptoms or greater impairment. I.e. Higher scores on the Nepean Dyspepsia Index indicate more severe dyspeptic symptoms and a greater impact on quality of life. Lower scores indicate milder symptoms and less impairment in quality of life. Therefore, a reduction in Nepean Dyspepsia Index scores in response to ginger supplementation indicates an improvement in symptoms and quality of life for individuals with dyspepsia. four weeks
Primary Body Fat Content Analysis Changes in body fat content, which will be assessed before and after four weeks of ginger supplementation using the In-Body 270, a non-invasive device that measures body weight, skeletal muscle mass, body fat, and other health parameters at five body parts using two different frequencies. This measure aims to evaluate the impact of Functional Dyspepsia and ginger supplementation on body composition, which could be relevant due to potential associations between functional dyspepsia and alterations in body fat distribution. Four weeks
Secondary Improvement in Quality of Life Improvements in quality of life will be assessed by the EuroQol Group's EQ-5D questionnaire before and after 4 weeks of ginger supplementation. EuroQol Group's EQ-5D consists of 2 main components:
Descriptive System: This part evaluates health status across 5 dimensions:
Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression Each is rated on a 3-level scale: 1: No problems to 3: Extreme problems
Visual Analog Scale (VAS): Respondents rate on a scale from 0 to 100, where: 0: Represents the worst imaginable health state 100: Represents the best imaginable health state
The values for EQ-5D ratings are as follows:
For each dimension in the descriptive system, the minimum value is 1 (indicating no problems) and the maximum value is 3 (indicating extreme problems).
For the VAS, the minimum value is 0 (worst imaginable health state) and the maximum value is 100 (best imaginable health state).
Four weeks
See also
  Status Clinical Trial Phase
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04464369 - Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial Phase 4
Completed NCT01671670 - Acupuncture for Patients With Function Dyspepsia Phase 2/Phase 3
Completed NCT00987805 - Efficacy of Banhasasim-tang on Functional Dyspepsia Phase 4
Completed NCT00693407 - Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation N/A
Completed NCT00761358 - To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia Phase 3
Recruiting NCT01240096 - Mirtazapine Versus Placebo in Functional Dyspepsia Phase 4
Recruiting NCT04540549 - Effects of Exercise on Functional Dyspepsia Based on Rome IV N/A
Recruiting NCT03652571 - Nortriptyline for the Treatment of Functional Dyspepsia Phase 3
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Recruiting NCT03825692 - International Clinical Study of Zhizhu Kuanzhong Capsule Phase 4
Not yet recruiting NCT04548011 - Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia N/A
Terminated NCT02567578 - A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia Phase 2
Completed NCT03007433 - Assessment of GI Function to a Large Test Meal by Non-invasive Imaging N/A
Active, not recruiting NCT00990405 - Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Phase 4
Completed NCT00404534 - Helicobacter Eradication Relief of Dyspeptic Symptoms Phase 3
Completed NCT03043625 - Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia N/A
Completed NCT03225248 - Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia Phase 3
Recruiting NCT05587127 - Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia N/A
Recruiting NCT01021475 - Does Visceral Manipulation Works in Treating Functional Dyspepsia? Phase 1